Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer

PLoS ONE

Volumn 3, Issue 8, 2008, Pages

  Musgrove, Elizabeth A ^a,b   Sergio, C Marcelo ^a   Loi, Sherene ^c   Inman, Claire K ^a   Anderson, Luke R ^a,b   Alles, M Chehani ^a,b   Pinese, Mark ^a   Caldon, C Elizabeth ^a,b   Schütte, Judith ^a   Gardiner Garden, Margaret ^a   Ormandy, Christopher J ^a,b   McArthur, Grant ^c,d   Butt, Alison J ^a,b   Sutherland, Robert L ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; MYC PROTEIN; SMALL INTERFERING RNA; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DNA;

ARTICLE; BIOGENESIS; BREAST CANCER; CANCER RESISTANCE; CELL CYCLE REGULATION; CELL DEATH; CELL GROWTH; CELL STRAIN MCF 7; CELL SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PREDICTION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; RIBOSOME; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; BREAST TUMOR; CELL CYCLE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; ONCOGENE MYC; PATHOLOGY; PHYSIOLOGY; REGRESSION ANALYSIS; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; DNA, NEOPLASM; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; PROTO-ONCOGENE PROTEINS C-MYC; REGRESSION ANALYSIS; TAMOXIFEN; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 52149122077     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002987     Document Type: Article

References (56)

1. Dellapasqua S, Colleoni M, Gelber RD, Goldhirsch A (2005) Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol 23: 1736-1750.
2. Strasser-Weippl K, Goss PE (2005) Advances in adjuvant hormonal therapy for postmenopausal women. J Clin Oncol 23: 1751-1759.
3. (EBCTCG) EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
4. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, et al. (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361: 296-300.
5. Jordan VC (2007) Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 7: 46-53.
6. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, et al. (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23: 5108-5116.
7. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-112.
8. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, et al. (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22: 7316-7339.
9. Nicholson RI, Hutcheson IR, Britton D, Knowlden JM, Jones HE, et al. (2005) Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. J Steroid Biochem Mol Biol 93: 257-262.
10. Loi S, Piccart M, Sotiriou C (2007) The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. Crit Rev Oncol Hematol 61: 187-194.
11. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, et al. (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25: 1239-1246.
12. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL (2005) Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 12: S47-S59.
13. Prall OWJ, Rogan EM, Musgrove EA, Watts CKW, Sutherland RL (1998) c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol 18: 4499-4508.
14. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423.
15. Musgrove EA, Wakeling AE, Sutherland RL (1989) Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle. Cancer Res 49: 2398-2404.
16. Tang S, Han H, Bajic VB (2004) ERGDB: Estrogen Responsive Genes Database. Nucleic Acids Res 32: D533-536.
17. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV (2003) An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 4: R69.
18. Butt AJ, Sergio CM, Inman CK, Anderson LR, McNeil CM, et al. (2008) The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome. Breast Cancer Res 10: R28.
19. Mukherjee S, Conrad SE (2005) c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem 280: 17617-17625.
20. Draghici S, Khatri P, Martins RP, Ostermeier GG, Krawetz SA (2003) Global functional profiling of gene expression. Genomics 81: 98-104.
21. Rhodes DR, Tomlins SA, Varambally S, Mahavisno V, Barrette T, et al. (2005) Probabilistic model of the human protein-protein interaction network. Nat Biotechnol 23: 951-959.
22. Andersen JS, Lam YW, Leung AK, Ong SE, Lyon CE, et al. (2005) Nucleolar proteome dynamics. Nature 433: 77-83.
23. Hinsby AM, Kiemer L, Karlberg EO, Lage K, Fausboll A, et al. (2006) A wiring of the human nueleolus. Mol Cell 22: 285-295.
24. White RJ (2005) RNA polymerases I and III, growth control and cancer. Nat Rev Mol Cell Biol 6: 69-78.
25. Bair E, Tibshirani R (2004) Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2: E108.
26. Adhikary S, Eilers M (2005) Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6: 635-645.
27. Cheng AS, Jin VX, Fan M, Smith LT, Liyanarachchi S, et al. (2006) Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. Mol Cell 21: 393-404.
28. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, et al. (2007) Non-transcriptional control of DNA replication by c-Myc. Nature 448: 445-451.
29. Leroy F, Bogaert C, Van Hoeck J (1975) DNA replication and accelerated chain growth in oestrogen-stimulated uterine cells. Nature 258: 259-260.
30. Lobenhofer EK, Bennett L, Cable PL, Li L, Bushel PR, et al. (2002) Regulation of DNA replication fork genes by 17beta-estradiol. Mol Endocrinol 16: 1215-1229.
31. Stender JD, Frasor J, Komm B, Chang KC, Kraus WL, et al. (2007) Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol Endocrinol 21: 2112-2123.
32. Lonard DM, Lanz RB, O'Malley BW (2007) Nuclear receptor coregulators and human disease. Endocr Rev 28: 575-587.
33. Saceda M, Lippman ME, Chambon P, Lindsey RL, Ponglikitmongkol M, et al. (1988) Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol Endocrinol 2: 1157-1162.
34. Hamilton TH (1968) Control by estrogen of genetic transcription and translation. Binding to chromatin and stimulation of nucleolar RNA synthesis are primary events in the early estrogen action. Science 161: 649-661.
35. Kirkland JL, Murthy L, Stancel GM (1992) Progesterone inhibits the estrogen-induced expression of c-fos messenger ribonucleic acid in the uterus. Endocrinology 130: 3223-3230.
36. Oskarsson T, Trumpp A (2005) The Myc trilogy: lord of RNA polymerases. Nat Cell Biol 7: 215-217.
37. Pratt MA, Krajewski S, Menard M, Krajewska M, Macleod H, et al. (1998) Estrogen withdrawal-induced human breast cancer tumour regression in nude mice is prevented by Bcl-2. FEBS Lett 440: 403-408.
38. Perillo B, Sasso A, Abbondanza C, Palumbo G (2000) 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20: 2890-2901.
39. Rodrik V, Zheng Y, Harrow F, Chen Y, Foster DA (2005) Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc. Mol Cell Biol 25: 7917-7925.
40. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826.
41. Oh DS, Troester MA, Usary J, Hu Z, He X, et al. (2006) Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24: 1656-1664.
42. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, et al. (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99: 167-170.
43. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, et al. (2007) Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39: 41-51.
44. Adler AS, Lin M, Horlings H, Nuyten DS, van de Vijver MJ, et al. (2006) Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet 38: 421-430.
45. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, et al. (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355: 560-569.
46. Butt AJ, Sutherland RL, Musgrove EA (2007) Does estrogen-mediated survival signalling play a role in endocrine responsiveness? Breast Cancer Res 9: 306 (doi:310.1186/bcr1779).
47. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, et al. (2005) Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23: 732-740.
48. Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, et al. (2007) Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 9: 470-478.
49. Daly RJ, Harris WH, Wang DY, Darbre PD (1991) Autocrine production of insulin-like growth factor II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells. Cell Growth Differ 2: 457-464.
50. Mukherjee B, Morgenbesser SD, DePinho RA (1992) Myc-family proteins function through a common pathway to transform normal cells in culture: cross-reference by Max and trans-acting dominant negative mutants. Genes Dev 6: 1480-1492.
51. Sutherland RL, Hall RE, Taylor IW (1983) Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res 43: 3998-4006.
52. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 272: 10882-10894.
53. Poortinga G, Hannan KM, Snelling H, Walkley CR, Jenkins A, et al. (2004) MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. Embo J 23: 3325-3335.
54. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
55. Smyth GK (2005) Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, eds. Bioinformatics and Computational Biology Solutions using R and Bioconductor. New York: Springer. pp 397-420.
56. Benjamini Y, Yekutieli D (2001) The control of the false discovery rate in multiple testing under dependency. Annals Statistics 29: 1165-1188.